Video

Dr. Mirza on the Impact of PARP Inhibitors in Ovarian Cancer

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the impact of PARP inhibitors in ovarian cancer.

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the impact of PARP inhibitors in ovarian cancer.

A retrospective analysis of the phase III ENGOT-OV16/NOVA trial showed that baseline body weight and platelet counts were early predictors for future adverse event-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

PARP inhibitors have changed the course of disease for patients with ovarian cancer, says Mirza. Next steps include investigating mechanisms of resistance, patient selection, and combinations with antiangiogeneic drugs and immune checkpoint inhibitors.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center